SAN.PA : Summary for SANOFI - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
75.62 -0.15 (-0.20%)
At close: 5:35PM CET
People also watch
FP.PA BN.PA CS.PA OR.PA AI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 75.77
Open 75.63
Bid 71.12 x 1000
Ask 71.74 x 44000
Day's Range 75.20 - 76.43
52 Week Range 62.50 - 79.07
Volume 3,349,301
Avg. Volume 2,930,280
Market Cap 94.94B
Beta 0.74
PE Ratio (TTM) 23.20
EPS (TTM) 3.26
Earnings Date Feb 8, 2017
Dividend & Yield 3.35 (4.12%)
Ex-Dividend Date N/A
1y Target Est 86.71
  • Reuters yesterday

    Pharma CEOs in Davos put brave face on Trump presidency

    Leaders of the global pharmaceutical industry, blasted by incoming U.S. President Donald Trump for "getting away with murder" on drug prices, are putting a brave face on the challenges in their biggest market.

  • Reuters yesterday

    Sanofi's M&A misses frustrate some investors in drugmaker

    PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.

  • The Wall Street Journal 2 days ago

    [$$] Rival to EpiPen Allergy Treatment to Return to Market

    The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products.

  • The Wall Street Journal 3 days ago

    [$$] Mallinckrodt Settles Antitrust Allegations on Unlawful Drug Monopoly

    Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug ...

  • MannKind Has a New Plan, but Will It Work?
    Motley Fool 3 days ago

    MannKind Has a New Plan, but Will It Work?

    MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?

  • Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
    Zacks 3 days ago

    Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

    Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

  • Reuters 3 days ago

    Drugmakers in Davos shift focus to chronic diseases of poor

    Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest an initial $50 million over three years to fight cancer and other non-communicable diseases in poor countries. Twenty-two companies, including Pfizer, Merck , Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank. The so-called Access Accelerated initiative was announced at the World Economic Forum in Davos and aims to improve both treatment and prevention.

  • Financial Times 3 days ago

    [$$] Drug companies pledge to improve emerging markets cancer care

    More than 20 of the world's leading drug companies have pledged to work together to treat cancer and other non-communicable diseases in poor and developing countries. Cancer and non-transmitted diseases ...

  • Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
    Investor's Business Daily 4 days ago

    Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad

    Regeneron and Sanofi argue Amgen's patents covering LDL-buster Repatha are too broad.

  • Forbes 5 days ago

    5 Trump-Proof Pharma Dividends Up To 5.3%

    Trump hasn’t yet entered the Oval Office, but he’s already showing an uncanny knack for creating quick stock dips with just a sentence or two.